Summary
43 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Revenue grew by 12% a year over the last 3 years.
- Out of every 100 USD of revenue, 12 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 4.5 years of operating profit.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 9.5% a year over 5 years. Over the last 3 years it grew by 12% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $1.77M.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 5.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Patient Income 55%
- Rental Income from Medical Services 45%
By region
- Domestic Segment 84%
- Foreign Segment 16%
Patient Income brings in 55% of revenue.
Segments in detail